SKIP TO
CONTENT
Philips Recalled CPAP, Bi-Level PAP, and Mechanical...
featured news
July 25, 2014
Healthcare Fraud
Pharmaceutical Company Astellas Settles False Claims Act Allegations With States
In an all-too-familiar scenario, pharmaceutical company Astellas, Inc. has agreed to settle all allegations against it involving the anti-fungal medication Mycamine. Earlier this year, the U.S. Department of Justice announced that it had reached an agreement with the company wherein it would remit over $7 million to the government pursuant […]
May 2, 2014
Healthcare Fraud
Pharmacy Company Astellas to Pay $7.3 Million in False Claims Act Settlement
The Department of Justice, in concert with several states’ attorneys general, recently announced a settlement against Astellas Pharma U.S., Inc., based in Northbrook, Illinois. The case involved substantial allegations of off-label marketing practices aimed at pediatric federal healthcare patients. As you well know, it is considered a violation of the […]
April 25, 2014
Healthcare Fraud
Pfizer Unsuccessful in Avoiding Off-Label Marketing False Claims Act Case
In a recent False Claims Act case involving the mental health drug Geodon, Pfizer reportedly lost its bid to have the case dismissed after unsuccessfully arguing, among other claims, that relators failed the “first-to-file” and “public disclosure” requirements contained within the language of the FCA. Specifically, the FCA precludes whistleblowers […]
March 25, 2014
Healthcare Fraud
Off-Label Marketing and the First Amendment: Are Pharmaceutical Companies Protected?
The issue of off-label marketing raises a compelling question as to the relationship between the First Amendment’s protection of free speech and the various federal regulations prohibiting the practice of unlawful marketing of prescription drugs. As a review, off-label marketing occurs when a pharmaceutical company markets its product for use […]
March 13, 2014
False Claims Act Legal News
U.S. Solicitor General Explains the Inapplicability of Rule 9(b) in the False Claims Act
As we reported yesterday, the U.S. Solicitor General, upon request by the Supreme Court, submitted its amicus curiae brief in the hotly-contested False Claims Act case Nathan v. Takeda Pharmaceuticals. As a bit of background, this case involves the practice of off-label marketing, which occurs when a drug company promotes […]
schedule a free consultation
"*" indicates required fields
By clicking SUBMIT you agree to our Terms of Use and Privacy Policy and you are providing express consent to receive communications from Berger Montague via calls, emails, and/or text messages.
$50B+
in Settlements & Verdicts
50+
Years of Experience With High-Profile Cases
100+
Attorneys Protecting Your Rights
20+
Years Ranked as Top Law Firm by Chambers USA
50
States in Which The Firm Has Successfully Litigated
On the Cutting Edge of the Profession
Legal Intelligencer
53
Years
